CanSino Biologics (CASBF) Stock Price, News & Analysis

Company Overview

CanSino Biologics Inc. is a China-based biopharmaceutical company focused on the research, development and commercialization of vaccine products. Headquartered in Tianjin, the company leverages an adenovirus vector platform to develop single-dose and recombinant vaccines targeting a range of infectious diseases. CanSino’s pipeline includes its authorized COVID-19 vaccine, Convidecia (Ad5-nCoV), as well as candidates for Ebola, influenza and other pathogens.

Since its founding in 2009, CanSino has built end-to-end capabilities spanning antigen discovery, process development and large-scale manufacturing. The company’s vaccine technologies are underpinned by a proprietary adenovirus type 5 vector system that supports streamlined production and robust immune responses. CanSino’s facilities are designed to meet international quality standards, enabling it to supply both domestic and overseas markets.

CanSino Biologics serves a broad geography, having secured emergency use authorizations or conditional approvals in China, Mexico, Pakistan, Hungary and several other countries for its COVID-19 vaccine. The company maintains partnerships with regional manufacturers and health authorities to facilitate distribution in Asia, Latin America and Europe. CanSino is led by a management team with extensive experience in vaccine science, regulatory affairs and commercial operations, positioning it as a key player in the global immunization landscape.

Key Stats

• Today's Range: C$2.95 to C$2.95
• 50-Day Range: C$2.95 to C$4.60
• 52-Week Range: C$2.60 to C$6.99
• Volume: N/A
• Average Volume: 559 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:CASBF
• CIK: N/A
• Web: www.cansinotech.com
• Phone: 400-922-2099
• Fax: N/A
• Employees: 1,494
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A